ECOG-ACRIN BY THE NUMBERS

Loading Quotes...

Announcements

Read the October issue of News from ECOG-ACRIN

The virtual Fall 2020 Group Meeting is in progress. View session schedule.

What to expect from the virtual meeting format

Read our Advocacy Blog on screening and surveillance

In case you missed it, the Q2 TMIST Study Updates Newsletter

Question about COVID19? Send an email

Latest News

NCI-MATCH data shows value of platform trials for patients with rare genomically driven cancers. Interview with lead investigator Keith T. Flaherty, MD, October 14, 2020. Precision Oncology News/GenomeWeb 

 

 

NCI-MATCH precision medicine cancer trial makes a major contribution to tumor gene testing for cancer treatment selection. Journal of Clinical Oncology publishes molecular analysis of 6000 NCI-MATCH patients. October 13, 2020. Read press release

 

 

Cancer care providers show varying attitudes, knowledge of LGBTQ patients, according to a survey by Matthew B. Schabath, PhD, and colleagues. October 6, 2020, Healio

 

 

ECOG-ACRIN’s new trial, EA2185, aims to settle the debate on the intensity of pancreatic cyst surveillance, October 1, 2020. Bulletin of the American College of Surgeons

 

 

Journal of the National Cancer Institute publishes final results of TAILORx substudy of race, ethnicity, and clinical outcomes in early breast cancer; Kathy S. Albain, MD (Loyola U), lead author. September 30, 2020, Read Article

 

 

 

Comparing the clinical impact of pancreatic cyst surveillance programs: EA2185. September 10, 2020, Contemporary Clinical Trials (subscription required)

 

TAILORx trial provides new insights into cancer-related cognitive impairment in early breast cancer, per Lynne Wagner, PhD (Wake Forest School of Medicine). September 1, 2020, MedPage Today

 

 

ENDURANCE trial results: There was no improvement in progression-free survival by replacing bortezomib with carfilzomib in the current standard initial treatment of patients with newly diagnosed standard- or intermediate-risk myeloma. August 28, 2020, The Lancet 

 

In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report on Arm H. The combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAFV600-mutated tumors outside of currently approved indications. August 13, 2020, OncLive

 

Results of the EA5161 trial are “striking ASCO 2020 data” and significant for patients with extensive small-cell lung cancer because adding nivolumab improved progression-free and overall survival. August 5, 2020, OncLive

 

 

Black Scientists Still Face an Uphill Battle in Securing NIH Research Grants: an interview with Edith P. Mitchell, MD (Thomas Jefferson U). “What we have to do is work in all areas and that’s what we’re doing in the ECOG-ACRIN Cancer Research Group, where I am a member of the executive committee.” July 15, 2020, Philadelphia Magazine

 

 

Taofeek Owonikoko, MD, PhD, MSCR (Emory U) on the results of trial EA5161: “Could there be unique differences between anti-PD-L1 and anti-PD-1 drugs? Possibly, however, I don’t think we can claim that such unique differences are significant enough to impact the efficacy of each in small-cell lung cancer.” July 15, 2020, Physician’s Weekly

 

For untreated follicular lymphoma, study E2408 shows that neither bortezomib added to bendamustine/rituximab (BR) induction nor lenalidomide added to rituximab maintenance immediately post-BR induction is recommended, per Andrew M. Evens, MD (Rutgers Cancer Institute of New Jersey) and colleagues. July 10, 2020, Clinical Cancer Research

 

 

Surprising Results from the PALLAS Trial: a discussion with Kathy D. Miller, MD (Indiana U). “More than anything else, this trial reminds us of the absolute necessity of putting our ideas to the test and doing appropriately powered, appropriately controlled, and well-conducted randomized trials.” July 1, 2020, Medscape

 

Study Shows Better Option for Treatment of Inoperable Anal Cancer: an article featuring Cathy Eng, MD (Vanderbilt U), lead investigator for InterAAct (EA2133), the first international prospective, randomized trial for advanced anal cancer. June 24, 2020, Science Magazine

 

Looking for more (older) news coverage? Visit the News and Info section and the TMIST Press Center.

YouTube Highlights

View our YouTube channel for these and other videos:

Acknowledgments

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

 

Robert L. Comis, MD
Group Co-Chair


Mitchell D. Schnall, MD, PhD
Group Co-Chair
img img
img
img